Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies.

Kuang J, Zhu J, Liu S, Li Q

Diabetes therapy : research, treatment and education of diabetes and related disorders28 Aug 2020Cited by 4 (Europe PMC)

PMID32857293PMCIDPMC7509013DOI10.1007/s13300-020-00910-1PepBankPUB-32857293

Read at source PubMedAsk about this study

Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study13

11 results from studies that gave the peptide. 11 results from people.

01HumanNon-randomized trialEfficacy outcome
In both age groups with diabetes, dulaglutide reduced HbA1c by 4 weeks and maintained the reduction through 26 weeks.
In plain wordsIn both age groups with diabetes, dulaglutide reduced average blood sugar by 4 weeks and maintained the reduction through 26 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c reduction time course
Study
n = 766
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 or 1.5 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
Dulaglutide showed a reduction in HbA1c as early as 4 weeks after initiation of treatment, which was maintained over 26 weeks in both age groups.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated the efficacy and safety of dulaglutide in Chinese patients with type 2 diabetes (T2D) aged ≥ 60 and < 60 years.
Summary · context
This post hoc analysis included patients with T2D enrolled in two phase 3 clinical trials AWARD-CHN1 (NCT01644500) and AWARD-CHN2 (NCT01648582) of dulaglutide 0.75 and 1.5 mg.
Report a problemFND-3285729309
02HumanNon-randomized trialEfficacy outcome
In older Chinese patients with diabetes, dulaglutide reduced HbA1c in AWARD-CHN1.
In plain wordsIn older Chinese patients with diabetes, dulaglutide reduced average blood sugar from baseline in AWARD-CHN1.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c in older patients, AWARD-CHN1, higher dose
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−1.45%
≥60 years, AWARD-CHN1, 1.5 mg
Source sentences
Summary
A similar reduction of HbA1c was observed in both age groups: AWARD-CHN1, 1.5 mg (least squares mean [LSM] 95% confidence interval [CI] ≥ 60 years: - 1.45% [- 1.69, - 1.21%] and < 60 years: - 1.43% [- 1.59, - 1.28%])
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated the efficacy and safety of dulaglutide in Chinese patients with type 2 diabetes (T2D) aged ≥ 60 and < 60 years.
Summary · context
This post hoc analysis included patients with T2D enrolled in two phase 3 clinical trials AWARD-CHN1 (NCT01644500) and AWARD-CHN2 (NCT01648582) of dulaglutide 0.75 and 1.5 mg.
Report a problemFND-3285729301
03HumanNon-randomized trialEfficacy outcome
In younger Chinese patients with diabetes, dulaglutide reduced HbA1c in AWARD-CHN1.
In plain wordsIn younger Chinese patients with diabetes, dulaglutide reduced average blood sugar from baseline in AWARD-CHN1.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c in younger patients, AWARD-CHN1, higher dose
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−1.43%
<60 years, AWARD-CHN1, 1.5 mg
Source sentences
Summary
A similar reduction of HbA1c was observed in both age groups: AWARD-CHN1, 1.5 mg (least squares mean [LSM] 95% confidence interval [CI] ≥ 60 years: - 1.45% [- 1.69, - 1.21%] and < 60 years: - 1.43% [- 1.59, - 1.28%])
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated the efficacy and safety of dulaglutide in Chinese patients with type 2 diabetes (T2D) aged ≥ 60 and < 60 years.
Summary · context
This post hoc analysis included patients with T2D enrolled in two phase 3 clinical trials AWARD-CHN1 (NCT01644500) and AWARD-CHN2 (NCT01648582) of dulaglutide 0.75 and 1.5 mg.
Report a problemFND-3285729302
04HumanNon-randomized trialEfficacy outcome
In older Chinese patients with diabetes, lower-dose dulaglutide reduced HbA1c in AWARD-CHN1.
In plain wordsIn older Chinese patients with diabetes, lower-dose dulaglutide reduced average blood sugar from baseline in AWARD-CHN1.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c in older patients, AWARD-CHN1, lower dose
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−1.29%
≥60 years, AWARD-CHN1, 0.75 mg
Source sentences
Summary
and 0.75 mg (≥ 60 years: - 1.29% [- 1.53, - 1.05%] and < 60 years: - 1.18% [- 1.33, - 1.03%]);
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated the efficacy and safety of dulaglutide in Chinese patients with type 2 diabetes (T2D) aged ≥ 60 and < 60 years.
Summary · context
This post hoc analysis included patients with T2D enrolled in two phase 3 clinical trials AWARD-CHN1 (NCT01644500) and AWARD-CHN2 (NCT01648582) of dulaglutide 0.75 and 1.5 mg.
Report a problemFND-3285729303
05HumanNon-randomized trialEfficacy outcome
In younger Chinese patients with diabetes, lower-dose dulaglutide reduced HbA1c in AWARD-CHN1.
In plain wordsIn younger Chinese patients with diabetes, lower-dose dulaglutide reduced average blood sugar from baseline in AWARD-CHN1.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c in younger patients, AWARD-CHN1, lower dose
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−1.18%
<60 years, AWARD-CHN1, 0.75 mg
Source sentences
Summary
and 0.75 mg (≥ 60 years: - 1.29% [- 1.53, - 1.05%] and < 60 years: - 1.18% [- 1.33, - 1.03%]);
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated the efficacy and safety of dulaglutide in Chinese patients with type 2 diabetes (T2D) aged ≥ 60 and < 60 years.
Summary · context
This post hoc analysis included patients with T2D enrolled in two phase 3 clinical trials AWARD-CHN1 (NCT01644500) and AWARD-CHN2 (NCT01648582) of dulaglutide 0.75 and 1.5 mg.
Report a problemFND-3285729304
06HumanNon-randomized trialEfficacy outcome
In older Chinese patients with diabetes, dulaglutide reduced HbA1c in AWARD-CHN2.
In plain wordsIn older Chinese patients with diabetes, dulaglutide reduced average blood sugar from baseline in AWARD-CHN2.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c in older patients, AWARD-CHN2, higher dose
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−1.6%
≥60 years, AWARD-CHN2, 1.5 mg
Source sentences
Summary
AWARD-CHN2, 1.5 mg (≥ 60 years: - 1.60% [- 1.83, - 1.36%] and < 60 years: - 1.64% [- 1.80, - 1.49%])
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated the efficacy and safety of dulaglutide in Chinese patients with type 2 diabetes (T2D) aged ≥ 60 and < 60 years.
Summary · context
This post hoc analysis included patients with T2D enrolled in two phase 3 clinical trials AWARD-CHN1 (NCT01644500) and AWARD-CHN2 (NCT01648582) of dulaglutide 0.75 and 1.5 mg.
Report a problemFND-3285729305
07HumanNon-randomized trialEfficacy outcome
In younger Chinese patients with diabetes, dulaglutide reduced HbA1c in AWARD-CHN2.
In plain wordsIn younger Chinese patients with diabetes, dulaglutide reduced average blood sugar from baseline in AWARD-CHN2.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c in younger patients, AWARD-CHN2, higher dose
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−1.64%
<60 years, AWARD-CHN2, 1.5 mg
Source sentences
Summary
AWARD-CHN2, 1.5 mg (≥ 60 years: - 1.60% [- 1.83, - 1.36%] and < 60 years: - 1.64% [- 1.80, - 1.49%])
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated the efficacy and safety of dulaglutide in Chinese patients with type 2 diabetes (T2D) aged ≥ 60 and < 60 years.
Summary · context
This post hoc analysis included patients with T2D enrolled in two phase 3 clinical trials AWARD-CHN1 (NCT01644500) and AWARD-CHN2 (NCT01648582) of dulaglutide 0.75 and 1.5 mg.
Report a problemFND-3285729306
08HumanNon-randomized trialEfficacy outcome
In older Chinese patients with diabetes, lower-dose dulaglutide reduced HbA1c in AWARD-CHN2.
In plain wordsIn older Chinese patients with diabetes, lower-dose dulaglutide reduced average blood sugar from baseline in AWARD-CHN2.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c in older patients, AWARD-CHN2, lower dose
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−1.31%
≥60 years, AWARD-CHN2, 0.75 mg
Source sentences
Summary
and 0.75 mg (≥ 60 years: - 1.31% [- 1.55, - 1.08%] and < 60 years: - 1.33% [- 1.48, - 1.17%]).
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated the efficacy and safety of dulaglutide in Chinese patients with type 2 diabetes (T2D) aged ≥ 60 and < 60 years.
Summary · context
This post hoc analysis included patients with T2D enrolled in two phase 3 clinical trials AWARD-CHN1 (NCT01644500) and AWARD-CHN2 (NCT01648582) of dulaglutide 0.75 and 1.5 mg.
Report a problemFND-3285729307
09HumanNon-randomized trialEfficacy outcome
In younger Chinese patients with diabetes, lower-dose dulaglutide reduced HbA1c in AWARD-CHN2.
In plain wordsIn younger Chinese patients with diabetes, lower-dose dulaglutide reduced average blood sugar from baseline in AWARD-CHN2.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c in younger patients, AWARD-CHN2, lower dose
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−1.33%
<60 years, AWARD-CHN2, 0.75 mg
Source sentences
Summary
and 0.75 mg (≥ 60 years: - 1.31% [- 1.55, - 1.08%] and < 60 years: - 1.33% [- 1.48, - 1.17%]).
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated the efficacy and safety of dulaglutide in Chinese patients with type 2 diabetes (T2D) aged ≥ 60 and < 60 years.
Summary · context
This post hoc analysis included patients with T2D enrolled in two phase 3 clinical trials AWARD-CHN1 (NCT01644500) and AWARD-CHN2 (NCT01648582) of dulaglutide 0.75 and 1.5 mg.
Report a problemFND-3285729308
10HumanObservational studySafety outcome
In Chinese patients receiving dulaglutide, hypoglycemia incidence was low in both age groups.
In plain wordsAmong Chinese patients receiving dulaglutide, low blood sugar events were uncommon in both age groups.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableHypoglycemia
Study
n = 766
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.75 or 1.5 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
Incidence of hypoglycemia and GI TEAEs was low in each age group.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated the efficacy and safety of dulaglutide in Chinese patients with type 2 diabetes (T2D) aged ≥ 60 and < 60 years.
Summary · context
This post hoc analysis included patients with T2D enrolled in two phase 3 clinical trials AWARD-CHN1 (NCT01644500) and AWARD-CHN2 (NCT01648582) of dulaglutide 0.75 and 1.5 mg.
Report a problemFND-3285729311
11HumanObservational studySafety outcome
In Chinese patients receiving dulaglutide, gastrointestinal adverse event incidence was low in both age groups.
In plain wordsAmong Chinese patients receiving dulaglutide, digestive adverse events were uncommon in both age groups.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableGastrointestinal TEAEs
Study
n = 766
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.75 or 1.5 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
Incidence of hypoglycemia and GI TEAEs was low in each age group.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated the efficacy and safety of dulaglutide in Chinese patients with type 2 diabetes (T2D) aged ≥ 60 and < 60 years.
Summary · context
This post hoc analysis included patients with T2D enrolled in two phase 3 clinical trials AWARD-CHN1 (NCT01644500) and AWARD-CHN2 (NCT01648582) of dulaglutide 0.75 and 1.5 mg.
Report a problemFND-3285729312

Studies that did not test the peptide alone2

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

12HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In Chinese patients receiving dulaglutide, HbA1c target achievement was similar between older and younger groups.
In plain wordsAmong Chinese patients receiving dulaglutide, older and younger groups reached the blood sugar target at similar rates.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeHbA1c target achievement by age
Study
n = 766
Comparator
Other age group
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The percentage of patients achieving HbA1c target < 7.0% at 26 weeks was also similar in both age groups.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated the efficacy and safety of dulaglutide in Chinese patients with type 2 diabetes (T2D) aged ≥ 60 and < 60 years.
Summary · context
This post hoc analysis included patients with T2D enrolled in two phase 3 clinical trials AWARD-CHN1 (NCT01644500) and AWARD-CHN2 (NCT01648582) of dulaglutide 0.75 and 1.5 mg.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3285729310
13HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In Chinese patients receiving dulaglutide, HbA1c reductions were similar between patients aged ≥60 and <60 years.
In plain wordsAmong Chinese patients receiving dulaglutide, blood sugar reductions were similar between older and younger age groups.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeHbA1c reduction by age
Study
n = 766
Comparator
Other age group
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c change (LSM)
−1.45%
AWARD-CHN1, 1.5 mg, age >=60 years, 26 weeks
HbA1c change (LSM)
−1.43%
AWARD-CHN1, 1.5 mg, age <60 years, 26 weeks
HbA1c change (LSM)
−1.29%
AWARD-CHN1, 0.75 mg, age >=60 years, 26 weeks
HbA1c change (LSM)
−1.18%
AWARD-CHN1, 0.75 mg, age <60 years, 26 weeks
HbA1c change (LSM)
−1.6%
AWARD-CHN2, 1.5 mg, age >=60 years, 26 weeks
HbA1c change (LSM)
−1.64%
AWARD-CHN2, 1.5 mg, age <60 years, 26 weeks
HbA1c change (LSM)
−1.31%
AWARD-CHN2, 0.75 mg, age >=60 years, 26 weeks
HbA1c change (LSM)
−1.33%
AWARD-CHN2, 0.75 mg, age <60 years, 26 weeks
Source sentences
Summary
A similar reduction of HbA1c was observed in both age groups: AWARD-CHN1, 1.5 mg (least squares mean [LSM] 95% confidence interval [CI] ≥ 60 years: - 1.45% [- 1.69, - 1.21%] and < 60 years: - 1.43% [- 1.59, - 1.28%])
Summary
and 0.75 mg (≥ 60 years: - 1.29% [- 1.53, - 1.05%] and < 60 years: - 1.18% [- 1.33, - 1.03%]);
Summary
AWARD-CHN2, 1.5 mg (≥ 60 years: - 1.60% [- 1.83, - 1.36%] and < 60 years: - 1.64% [- 1.80, - 1.49%]) and 0.75 mg (≥ 60 years: - 1.31% [- 1.55, - 1.08%] and < 60 years: - 1.33% [- 1.48, - 1.17%]).
3 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated the efficacy and safety of dulaglutide in Chinese patients with type 2 diabetes (T2D) aged ≥ 60 and < 60 years.
Summary · context
This post hoc analysis included patients with T2D enrolled in two phase 3 clinical trials AWARD-CHN1 (NCT01644500) and AWARD-CHN2 (NCT01648582) of dulaglutide 0.75 and 1.5 mg.
Summary · context
A total of 766 patients (≥ 60 years, n = 222; < 60 years, n = 544) were included in the study.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3285729313

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01644500

A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus

Eli Lilly and Companyn = 737Jul 2012 to Aug 2014

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 18 Sept 2019

CompletedPhase 3Results postedNCT01648582

A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus

Eli Lilly and Companyn = 774Jul 2012 to Dec 2014

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 18 Sept 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.